577 related articles for article (PubMed ID: 19031175)
1. Review of MammoSite brachytherapy: advantages, disadvantages and clinical outcomes.
Bensaleh S; Bezak E; Borg M
Acta Oncol; 2009; 48(4):487-94. PubMed ID: 19031175
[TBL] [Abstract][Full Text] [Related]
2. Five-year results: the initial clinical trial of MammoSite balloon brachytherapy for partial breast irradiation in early-stage breast cancer.
Benitez PR; Keisch ME; Vicini F; Stolier A; Scroggins T; Walker A; White J; Hedberg P; Hebert M; Arthur D; Zannis V; Quiet C; Streeter O; Silverstein M
Am J Surg; 2007 Oct; 194(4):456-62. PubMed ID: 17826055
[TBL] [Abstract][Full Text] [Related]
3. Preliminary results and evaluation of MammoSite balloon brachytherapy for partial breast irradiation for pure ductal carcinoma in situ: a phase II clinical study.
Benitez PR; Streeter O; Vicini F; Mehta V; Quiet C; Kuske R; Hayes MK; Arthur D; Kuerer H; Freedman G; Keisch M; Dipetrillo T; Khan D; Hudes R
Am J Surg; 2006 Oct; 192(4):427-33. PubMed ID: 16978943
[TBL] [Abstract][Full Text] [Related]
4. Cosmetic outcome and incidence of infection with the MammoSite breast brachytherapy applicator.
Dickler A; Kirk MC; Choo J; Hsi WC; Chu J; Dowlatshahi K; Francescatti D; Shott S; Nguyen C
Breast J; 2005; 11(5):306-10. PubMed ID: 16174149
[TBL] [Abstract][Full Text] [Related]
5. MammoSite accelerated partial breast irradiation: a single-institution outcomes analysis with 2 years of followup.
Haley M; Beriwal S; Heron DE; Kim H; Falk J; Johnson R; Mogus R
Brachytherapy; 2009; 8(1):9-13. PubMed ID: 18955020
[TBL] [Abstract][Full Text] [Related]
6. Analysis of treatment efficacy, cosmesis, and toxicity using the MammoSite breast brachytherapy catheter to deliver accelerated partial-breast irradiation: the william beaumont hospital experience.
Chao KK; Vicini FA; Wallace M; Mitchell C; Chen P; Ghilezan M; Gilbert S; Kunzman J; Benitez P; Martinez A
Int J Radiat Oncol Biol Phys; 2007 Sep; 69(1):32-40. PubMed ID: 17467920
[TBL] [Abstract][Full Text] [Related]
7. Treatment volume and dose optimization of MammoSite breast brachytherapy applicator.
Dickler A; Kirk M; Choo J; Hsi WC; Chu J; Dowlatshahi K; Francescatti D; Nguyen C
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):469-74. PubMed ID: 15145164
[TBL] [Abstract][Full Text] [Related]
8. Early European experience with the MammoSite radiation therapy system for partial breast brachytherapy following breast conservation operation in low-risk breast cancer.
Niehoff P; Ballardini B; Polgár C; Major T; Hammer J; Richetti A; Kovács G
Breast; 2006 Jun; 15(3):319-25. PubMed ID: 16765284
[TBL] [Abstract][Full Text] [Related]
9. First analysis of patient demographics, technical reproducibility, cosmesis, and early toxicity: results of the American Society of Breast Surgeons MammoSite breast brachytherapy trial.
Vicini FA; Beitsch PD; Quiet CA; Keleher A; Garcia D; Snider HC; Gittleman MA; Zannis VJ; Kuerer H; Whitacre EB; Whitworth PW; Fine RE; Haffty BG; Arrambide LS
Cancer; 2005 Sep; 104(6):1138-48. PubMed ID: 16088962
[TBL] [Abstract][Full Text] [Related]
10. Acute complications of MammoSite brachytherapy: a single institution's initial clinical experience.
Harper JL; Jenrette JM; Vanek KN; Aguero EG; Gillanders WE
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):169-74. PubMed ID: 15629608
[TBL] [Abstract][Full Text] [Related]
11. Clinical experience with the MammoSite radiation therapy system for brachytherapy of breast cancer: results from an international phase II trial.
Niehoff P; Polgár C; Ostertag H; Major T; Sulyok Z; Kimmig B; Kovács G
Radiother Oncol; 2006 Jun; 79(3):316-20. PubMed ID: 16780977
[TBL] [Abstract][Full Text] [Related]
12. Long-term cosmesis after lumpectomy and brachytherapy in the management of carcinoma of the previously irradiated breast.
Trombetta M; Julian TB; Werts DE; McWilliams W; Kim Y; Miften M; Parda D
Am J Clin Oncol; 2009 Jun; 32(3):314-8. PubMed ID: 19451803
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with optimal cosmetic results at 36 months in patients treated with accelerated partial breast irradiation (APBI) on the American Society of Breast Surgeons (ASBrS) MammoSite Breast Brachytherapy Registry Trial.
Goyal S; Khan AJ; Vicini F; Beitsch PD; Lyden M; Keisch M; Haffty BG
Ann Surg Oncol; 2009 Sep; 16(9):2450-8. PubMed ID: 19517191
[TBL] [Abstract][Full Text] [Related]
14. Multi-institutional experience using the MammoSite radiation therapy system in the treatment of early-stage breast cancer: 2-year results.
Cuttino LW; Keisch M; Jenrette JM; Dragun AE; Prestidge BR; Quiet CA; Vicini FA; Rescigno J; Wazer DE; Kaufman SA; Ramakrishnan VR; Patel R; Arthur DW
Int J Radiat Oncol Biol Phys; 2008 May; 71(1):107-14. PubMed ID: 18037585
[TBL] [Abstract][Full Text] [Related]
15. Three-year analysis of treatment efficacy, cosmesis, and toxicity by the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial in patients treated with accelerated partial breast irradiation (APBI).
Vicini F; Beitsch PD; Quiet CA; Keleher AJ; Garcia D; Snider HC; Gittleman MA; Zannis VJ; Kuerer HM; Lyden M
Cancer; 2008 Feb; 112(4):758-66. PubMed ID: 18181095
[TBL] [Abstract][Full Text] [Related]
16. Acute toxicity of high-dose-rate intracavitary brachytherapy with the MammoSite applicator in patients with early-stage breast cancer.
Richards GM; Berson AM; Rescigno J; Sanghavi S; Siegel B; Axelrod D; Bernik S; Scarpinato V; Mills C
Ann Surg Oncol; 2004 Aug; 11(8):739-46. PubMed ID: 15249336
[TBL] [Abstract][Full Text] [Related]
17. MammoSite and interstitial brachytherapy for accelerated partial breast irradiation: factors that affect toxicity and cosmesis.
Shah NM; Tenenholz T; Arthur D; DiPetrillo T; Bornstein B; Cardarelli G; Zheng Z; Rivard MJ; Kaufman S; Wazer DE
Cancer; 2004 Aug; 101(4):727-34. PubMed ID: 15305402
[TBL] [Abstract][Full Text] [Related]
18. The MammoSite breast brachytherapy applicator: a review of technique and outcomes.
Dickler A; Kirk MC; Chu J; Nguyen C
Brachytherapy; 2005; 4(2):130-6. PubMed ID: 15893266
[TBL] [Abstract][Full Text] [Related]
19. Partial breast irradiation as sole therapy for low risk breast carcinoma: early toxicity, cosmesis and quality of life results of a MammoSite brachytherapy phase II study.
Belkacémi Y; Chauvet MP; Giard S; Villette S; Lacornerie T; Bonodeau F; Baranzelli MC; Bonneterre J; Lartigau E
Radiother Oncol; 2009 Jan; 90(1):23-9. PubMed ID: 18692927
[TBL] [Abstract][Full Text] [Related]
20. Initial outcomes for patients treated on the American Society of Breast Surgeons MammoSite clinical trial for ductal carcinoma-in-situ of the breast.
Jeruss JS; Vicini FA; Beitsch PD; Haffty BG; Quiet CA; Zannis VJ; Keleher AJ; Garcia DM; Snider HC; Gittleman MA; Whitacre E; Whitworth PW; Fine RE; Arrambide S; Kuerer HM
Ann Surg Oncol; 2006 Jul; 13(7):967-76. PubMed ID: 16788759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
